Rates of ME/CFS were higher in MPO-ANCA patients than in PR3-ANCA patients, with 61.5% (16/26) of MPO-ANCA patients having ME/CFS, compared to 42.3% (11/26) of PR3-ANCA patients, though this was not statistically significant (Supplementary Table S1). The gene discussed is MPO; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.